STOCK TITAN
  1. Home
  2. News
  3. SGHT

Sight Sciences, Inc. - SGHT STOCK NEWS

Welcome to our dedicated page for Sight Sciences news (Ticker: SGHT), a resource for investors and traders seeking the latest updates and insights on Sight Sciences stock.

Sight Sciences, Inc., headquartered in Menlo Park, California, is a prominent medical device company dedicated to innovating and commercializing cutting-edge technologies for the treatment of prevalent eye diseases. The company operates through two main segments: Surgical Glaucoma and Dry Eye.

In the Surgical Glaucoma segment, Sight Sciences offers the OMNI Surgical System. This versatile device allows for both canaloplasty and trabeculotomy with a single corneal incision, aimed at reducing intraocular pressure in adults with primary open-angle glaucoma. The efficacy of OMNI has been demonstrated in multiple clinical trials, showing favorable outcomes in lowering intraocular pressure across various stages of glaucoma.

In the Dry Eye segment, the TearCare System is available for ophthalmologists and optometrists. This system helps manage dry eye disease through a single interventional eyelid procedure, providing significant improvements in the signs and symptoms of the condition over time.

Recent clinical trials have highlighted the effectiveness of these devices. For example, the GEMINI Study demonstrated successful results using OMNI combined with cataract surgery, and the SAHARA trial confirmed the benefits of TearCare compared to traditional treatments.

Financially, Sight Sciences derives key revenue from its Surgical Glaucoma segment. The company has seen active customer engagement, as evidenced by the number of OMNI and SION system orders, as well as TearCare SmartLids sales.

For investors and stakeholders, Sight Sciences continues to be a compelling entity with its relentless focus on reimagining eye care through transformative technologies. The company's commitment to improving patient outcomes and expanding its market presence underscores its significance in the ophthalmic medical device industry.

News

Sight Sciences Announces European Launch of the Ergo-Series of the OMNI® Surgical System at the ESCRS Winter Meeting

Rhea-AI Summary
Sight Sciences, Inc. (Nasdaq: SGHT) launches the Ergo-Series of the OMNI Surgical System in Europe, enhancing minimally invasive glaucoma procedures. The technology aims to improve ergonomics and precision for surgeons, receiving positive feedback in the US and CE Mark approval for the EU market.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.7%
Tags
none
-
News

Sight Sciences Announces the Closing of up to $65 Million Senior Secured Credit Facility with Hercules Capital

Rhea-AI Summary
Sight Sciences, Inc. (SGHT) announced the closing of a $65 million senior secured credit facility with Hercules Capital, Inc. The transaction included an immediate draw of $35 million, used to pay off the principal amount of the Company’s indebtedness to its previous secured lender. The new facility strengthens the company's balance sheet and enhances its ability to execute its strategic plan. The capital commitment aims to help Sight Sciences deliver on its mission to transform the treatment of eye diseases by treating the underlying causes. The credit facility terms include a 54-month maturity, with an interest-only period of 30 months, which can be extended to 36 months subject to certain performance milestones.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-11.28%
Tags
none
-
News

Sight Sciences Announces Preliminary, Unaudited Fourth Quarter and Full Year 2023 Financial Highlights

Rhea-AI Summary
Sight Sciences, Inc. (Nasdaq: SGHT) reported preliminary financial highlights for Q4 and full year 2023, with total revenue expected to be $18.6-18.8 million for Q4, a 9% decrease, and $80.9-81.1 million for the full year, a 14% increase. Cash and cash equivalents as of Dec 31, 2023, were approximately $138 million. The company's Q4 and full year 2023 financial results are preliminary and subject to audit, with complete results expected in March 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.11%
Tags
none
News

Sight Sciences Announces Withdrawal of Final LCDs on Micro-Invasive Glaucoma Surgery from Five Medicare Administrative Contractors

Rhea-AI Summary
Sight Sciences, Inc. (Nasdaq: SGHT) supports the decision by five Medicare Administrative Contractors to withdraw their final local coverage determinations for Micro-Invasive Glaucoma Surgery, ensuring continued access to comprehensive outflow procedure enabled by OMNI Surgical System technology for glaucoma patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.63%
Tags
none
-
News

Sight Sciences Announces the Publication of Successful Results of the SAHARA Randomized Controlled Clinical Trial Comparing TearCare® to Restasis® for the Treatment of Dry Eye Disease

Rhea-AI Summary
Sight Sciences, Inc. (Nasdaq: SGHT) announced the publication of the six-month primary results from the SAHARA randomized controlled trial, demonstrating the superior efficacy of interventional eyelid procedures enabled by TearCare technology over Restasis in addressing the underlying causes of evaporative dry eye.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.13%
Tags
clinical trial
-
News

Sight Sciences Announces the Acceptance for Publication of GEMINI 2, a Three Year, Prospective, Multicenter Trial Demonstrating Sustained, Significant IOP and Medication Reductions Enabled with the OMNI® Surgical System Technology

Rhea-AI Summary
Sight Sciences, Inc. (Nasdaq: SGHT) announced the acceptance for publication of the prospective, multi-center, three-year GEMINI 2 trial with long-term clinical outcomes for patients treated with the OMNI Surgical System technology. The trial demonstrated sustained and clinically significant intraocular pressure reduction of greater than 20% and clinically significant IOP lowering medication reduction at 36 months. The data further supports the need for continued access to OMNI technology.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.3%
Tags
none
News

Sight Sciences Reports Third Quarter 2023 Financial Results and Withdraws Guidance for Full Year 2023

Rhea-AI Summary
Sight Sciences, Inc. (Nasdaq: SGHT) reported Q3 2023 revenue of $20.0 million, a 7% increase YoY. The company withdrew its full year 2023 guidance due to uncertainties caused by a recent LCD that would limit Medicare patient access to a key procedure. The company also appointed a new Chief Commercial Officer and implemented cost-saving initiatives.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.9%
Tags
earnings
-
News

Sight Sciences to Report Third Quarter 2023 Financial Results on November 7, 2023

Rhea-AI Summary
Sight Sciences, Inc. will report financial results for Q3 2023 on November 7th. The company's management will discuss the results during a conference call.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.69%
Tags
conferences earnings
-
News

Sight Sciences to Host SAHARA 6 Month RCT Results Reception at the American Academy of Ophthalmology 2023

Rhea-AI Summary
Sight Sciences announces TearCare SAHARA Six Month RCT Results reception
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.55%
Tags
conferences
News

Sight Sciences Announces Presentation of Successful Phase I Results of the SAHARA Randomized Controlled Clinical Trial Comparing TearCare® to Restasis® for the Treatment of Dry Eye Disease at the American Academy of Optometry Annual Meeting

Rhea-AI Summary
Sight Sciences announces positive results from the SAHARA trial, demonstrating the superiority of TearCare technology over Restasis eyedrops for the treatment of dry eye disease. TearCare showed statistically significant improvements in tear break up time and other objective signs of dry eye compared to Restasis. Both treatments delivered comparable improvements in patient-reported outcomes. TearCare offers an efficacious and durable interventional dry eye treatment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.83%
Tags
clinical trial

FAQ

What is the current stock price of Sight Sciences (SGHT)?

The current stock price of Sight Sciences (SGHT) is $4.01 as of November 22, 2024.

What is the market cap of Sight Sciences (SGHT)?

The market cap of Sight Sciences (SGHT) is approximately 204.4M.

What does Sight Sciences, Inc. do?

Sight Sciences, Inc. develops and commercializes surgical and nonsurgical technologies for treating prevalent eye diseases, focusing on glaucoma and dry eye disease.

What products are offered by Sight Sciences in the Surgical Glaucoma segment?

Sight Sciences offers the OMNI Surgical System, which facilitates canaloplasty and trabeculotomy to reduce intraocular pressure in patients with primary open-angle glaucoma.

What is the TearCare System?

The TearCare System is a product in Sight Sciences' Dry Eye segment designed for managing dry eye disease through an interventional eyelid procedure.

Where is Sight Sciences, Inc. headquartered?

Sight Sciences, Inc. is headquartered in Menlo Park, California, United States.

What were the findings of the GEMINI Study?

The GEMINI Study showed successful 12-month and 36-month results of the OMNI Surgical System combined with cataract surgery for glaucoma patients.

How does Sight Sciences contribute to treating dry eye disease?

Sight Sciences contributes to treating dry eye disease through its TearCare System, which has shown significant improvements in clinical trials.

What financial segment drives Sight Sciences' revenue?

Sight Sciences derives key revenue from its Surgical Glaucoma segment.

Who can I contact for investor relations at Sight Sciences?

For investor relations, contact Philip Taylor at Gilmartin Group via email at Investor.Relations@SightSciences.com or phone at 415.937.5406.

Are there any recent clinical highlights for Sight Sciences?

Yes, recent clinical highlights include the GEMINI Study for glaucoma and the SAHARA trial for dry eye disease, both showing favorable outcomes.

What trademarks does Sight Sciences hold?

Sight Sciences holds trademarks for Sight Sciences, TearCare, OMNI, and SION in the United States and other territories.

Stock SGHT logo
Sight Sciences, Inc.

Nasdaq:SGHT

SGHT Rankings

#3841 Ranked by Market Cap
N/A Ranked by Dividends

SGHT Stock Data

204.36M
40.24M
19.9%
51.1%
2.23%
Medical Devices
Surgical & Medical Instruments & Apparatus
Link
United States of America
MENLO PARK